Ken Hawkins, 77, may have received an experimental drug on Oct. 31, or a placebo. Either way, he's the first Oregon participant in a first-ever trial of a gene-editing infusion added to the bloodstream to stop the worsening of a potentially fatal heart condition.
November 21, 2024
Image
Oregon Health & Science University
|
MICHAEL MCDERMOTT/OHSU
Ken Hawkins doesn’t play the lottery and isn’t much of a gambler. But on Oct.
